Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03500549 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 3 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT03500549 is a Phase 3 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT03500549, a Phase 3 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria
Interventions
- DRUG Pegcetacoplan
- DRUG Soliris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03500549
The ClinicalTrials.gov registry entry for NCT03500549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pegcetacoplan is the first listed.
NCT03500549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03500549 about?
NCT03500549 is a clinical study titled "Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria
What is the current status of trial NCT03500549?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2018-06-14. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03500549?
The interventions under investigation include: Pegcetacoplan (DRUG), Soliris (DRUG).
Who is sponsoring clinical trial NCT03500549?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.